Optimization and Verification of a Novel Trileaflet Polymeric Prosthetic Heart Valve

Valvular heart disease remains a significant public health issue with Calcific Aortic Valve Disease (CAVD) its most life threatening form. Current treatment for CAVD involves open-heart surgical replacement of the diseased aortic valve (AV) with either a tissue (THV) or mechanical (MHV) prosthesis, with THVs being mostly nonthrombogenic but vulnerable to structural valve deterioration (SVD) and MHVs being highly durable but thrombogenic, thus requiring lifelong anticoagulant therapy.

Go to article »

Join over 5000 cardiovascular device professionals who receive our testing and engineering insights and tips every month.